Foundation S: CCI and Foundation S are aligned in ensuring every child with cancer has an equal chance of survival. Treatment abandonment, a factor affecting the significant variations of survival rates globally, is avoidable through access to accommodation, which improves treatment adherence, leading to increased survival rates. Due to this, through the support of Foundation S, CCI launched the HAFH programme. The CCI community greatly appreciates this impactful and valuable support. 

LRP:  La Fondation La Roche-Posay, a strategic and valued partner, has munificently invested in CCI’s general operations, including the governing body, staff and general administration, and has supported the expansion of the CCI staff team. This has a multiplying effect, allowing us to acquire more resources for our programmes. La Fondation La Roche-Posay has invested in numerous projects, namely G2C, the development of our Knowledge Portal and sponsorship of training that occurs at the annual CCI conference. Thanks to La Fondation La Roche-Posay’s pivotal investment and unwavering support, this year CCI has significantly grown its organisational capacity, global advocacy and awareness. 

Servier and ACT for Children: Access Cancer Treatment (ACT) for Children is a multi-stakeholder initiative uniting industry, the medical community, and patient advocates to safely introduce innovative child cancer therapies in LMICs.
Through a partnership with Servier Group, the ACT for Children initiative was launched under their leadership. It aims to bring life-saving support to treatment centres in target countries with a significant lack of essential medicines and where additional support is needed for the hospital/treatment centres and the support organisations. The goal is to provide holistic support to eradicate barriers to treatment and care. This partnership involves numerous global organisations, including SIOP, the IDA Foundation, Resonance and World Child Cancer. Servier provides proprietary drugs at highly subsidised prices, significantly reducing financial barriers to life-saving treatments.